References
- Kearney P. M., Whelton M., Reynolds K., Muntner P., Whelton P. K., He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365: 217–223
- Levenson J. W., Skerrett P. J., Gaziano J. M. Reducing the global burden of cardiovascular disease: The role of risk factors. Prev Cardiol 2002; 5: 188–199
- Murray C. J., Lopez A. D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269–1276
- Erdine S., Aran S. N. Current status of hypertension control around the world. Clin Exp Hypertens 2004; 26: 731–738
- Hedner T., Narkiewicz K., Kjeldsen S. E. Hypertension control – A global challenge. Blood Press 2005; 14 Suppl: 4–5
- Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L Jr., , National Heart, Lung and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordination Committee, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560–2572
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA 2002; 288: 2981–2997
- Dunlay M. C., Fitzpatrick V., Chrysant S., Francischetti E. A., Goldberg A. I., Sweet C. S. Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens 1995; 9: 861–867
- Cifkova R., Peleska J., Hradec J., Rosolova H., Pinterova E., Zeman K., et al. Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens 1998; 12: 563–567
- Oparil S. Candesartan cilexetil in combination with low‐dose hydrochlorothiazide is effective in severe hypertension. Am J Cardiol 1999; 84: 35S–41S
- Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011–1053
- Tatti P., Pahor M., Byington R. P., Di Mauro P., Guarisco R., Strollo G., et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603
- PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–1041
- Neutel J. M., Smith D. H., Weber M. A. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens 2004; 17: 37–42
- Jamerson K., Bakris G. L., Dahlöf B., Pitt B., Velasques E., Gupte J., , for the ACCOMPLISH investigators, et al. Exceptional blood pressure control rates: The ACCOMPLISH trial. Blood Press 2007; 16: 80–86
- European Medicines Agency. Concept paper on the need for regulatory guidance in the evaluation of medicinal products for a first‐line indication of fixed combination medicinal products in therapeutic doses in the treatment of hypertension., Doc. Ref. CHMP/EWP/358529/2006. London, 21 September 2006